PortfoliosLab logo
SEER vs. GANX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SEER and GANX is 1.00, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Performance

SEER vs. GANX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Seer, Inc. (SEER) and Gain Therapeutics, Inc. (GANX). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

SEER:

42.55%

GANX:

84.95%

Max Drawdown

SEER:

-6.60%

GANX:

-6.90%

Current Drawdown

SEER:

-6.60%

GANX:

-4.43%

Fundamentals

Market Cap

SEER:

$109.35M

GANX:

$57.09M

EPS

SEER:

-$1.39

GANX:

-$0.89

PS Ratio

SEER:

7.72

GANX:

255.50

PB Ratio

SEER:

0.33

GANX:

7.78

Total Revenue (TTM)

SEER:

$14.91M

GANX:

$0.00

Gross Profit (TTM)

SEER:

$6.03M

GANX:

-$20.59K

EBITDA (TTM)

SEER:

-$92.11M

GANX:

-$15.91M

Returns By Period


SEER

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

GANX

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SEER vs. GANX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SEER
The Risk-Adjusted Performance Rank of SEER is 3434
Overall Rank
The Sharpe Ratio Rank of SEER is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of SEER is 2929
Sortino Ratio Rank
The Omega Ratio Rank of SEER is 3030
Omega Ratio Rank
The Calmar Ratio Rank of SEER is 4040
Calmar Ratio Rank
The Martin Ratio Rank of SEER is 3030
Martin Ratio Rank

GANX
The Risk-Adjusted Performance Rank of GANX is 3838
Overall Rank
The Sharpe Ratio Rank of GANX is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of GANX is 4444
Sortino Ratio Rank
The Omega Ratio Rank of GANX is 4343
Omega Ratio Rank
The Calmar Ratio Rank of GANX is 2929
Calmar Ratio Rank
The Martin Ratio Rank of GANX is 3232
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SEER vs. GANX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Seer, Inc. (SEER) and Gain Therapeutics, Inc. (GANX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

SEER vs. GANX - Dividend Comparison

Neither SEER nor GANX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SEER vs. GANX - Drawdown Comparison

The maximum SEER drawdown since its inception was -6.60%, roughly equal to the maximum GANX drawdown of -6.90%. Use the drawdown chart below to compare losses from any high point for SEER and GANX. For additional features, visit the drawdowns tool.


Loading data...

Volatility

SEER vs. GANX - Volatility Comparison


Loading data...

Financials

SEER vs. GANX - Financials Comparison

This section allows you to compare key financial metrics between Seer, Inc. and Gain Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00M2.00M3.00M4.00M20212022202320242025
3.95M
0
(SEER) Total Revenue
(GANX) Total Revenue
Values in USD except per share items